Inventiva To Present The Results Of LEGEND Phase IIa Combination Trial With lanifibranor And Empagliflozin In Patients With MASH/NASH And T2D In An Investor Conference On Tuesday, March 19
Portfolio Pulse from Benzinga Newsdesk
Inventiva (NASDAQ:IVA), a biopharmaceutical company, will present the results of the LEGEND Phase IIa trial on March 19, 2024. The trial evaluates lanifibranor in combination with empagliflozin for treating MASH/NASH and T2D. The study aims to assess the safety and efficacy of this combination, with primary efficacy endpoint being the change in Hemoglobin A1c at week 24. Lanifibranor, a pan-PPAR agonist, has received FDA Breakthrough Therapy and Fast Track designation for MASH/NASH treatment.
March 13, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inventiva is set to present significant trial results for its leading product candidate, lanifibranor, in combination with empagliflozin for MASH/NASH and T2D treatment on March 19, 2024.
The presentation of the LEGEND Phase IIa trial results is a critical event for Inventiva, as it could significantly impact the company's valuation and future prospects. Positive results could lead to increased investor confidence and a potential rise in stock price, given the FDA's Breakthrough Therapy and Fast Track designation for lanifibranor. The focus on a novel treatment for MASH/NASH and T2D, areas with high unmet medical needs, further underscores the importance of these results.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100